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Succinate dehydrogenase (complex II or succinate:ubiquinone oxidoreductase) is a tetrameric, membrane-bound enzyme that catalyzes the
oxidation of succinate and the reduction of ubiquinone in the mitochondrial respiratory chain. Two electrons from succinate are transferred one at a
time through a flavin cofactor and a chain of iron–sulfur clusters to reduce ubiquinone to an ubisemiquinone intermediate and to ubiquinol.
Residues that form the proximal quinone-binding site (QP) must recognize ubiquinone, stabilize the ubisemiquinone intermediate, and protonate
the ubiquinone to ubiquinol, while minimizing the production of reactive oxygen species. We have investigated the role of the yeast Sdh4p Tyr-89,
which forms a hydrogen bond with ubiquinone in the QP site. This tyrosine residue is conserved in all succinate:ubiquinone oxidoreductases
studied to date. In the human SDH, mutation of this tyrosine to cysteine results in paraganglioma, tumors of the parasympathetic ganglia in the
head and neck. We demonstrate that Tyr-89 is essential for ubiquinone reductase activity and that mutation of Tyr-89 to other residues does not
increase the production of reactive oxygen species. Our results support a role for Tyr-89 in the protonation of ubiquinone and argue that the
generation of reactive oxygen species is not causative of tumor formation.
© 2006 Elsevier B.V. All rights reserved.Keywords: Mitochondria; Yeast; Succinate:ubiquinone oxidoreductase; Complex II1. Introduction
Succinate dehydrogenase (SDH)1 of the mitochondrial
respiratory chain (MRC) is intriguing because of its importance
in energy generation and in mitochondria-related diseases. SDH,
also referred to as complex II, functions as a succinate–
ubiquinone oxidoreductase, oxidizing succinate to fumarate and
reducing ubiquinone to ubiquinol. The yeast enzyme, like its
mammalian counterpart, is encoded by four nuclear genes,
SDH1-4. Electron transport from the succinate-binding site to
the first or proximal quinone-binding site (QP) is along a chain of
redox groups that includes a covalently attached FAD and three
iron–sulfur clusters. In addition to these redox groups, the yeast
enzyme contains a b-type heme and a second or distal quinone-
binding site (QD), the roles of which remain controversial [1].
SDH is composed of two domains; the catalytic domain,
containing the flavoprotein Sdh1p and the iron–sulfur Sdh2p⁎ Corresponding author. Tel.: +1 780 492 4853; fax: +1 780 492 0886.
E-mail address: bernard.lemire@ualberta.ca (B.D. Lemire).
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doi:10.1016/j.bbabio.2006.11.017subunits, is linked to the mitochondrial inner membrane surface
by association with the membrane domain. The membrane
domain is composed of the two hydrophobic subunits, Sdh3p
and Sdh4p, which house the heme and the quinone-binding
sites. SDH structures of the Escherichia coli [2,3], the porcine
heart [4], the chicken heart [5] and the Saccharomyces
cerevisiae [6] enzymes have been determined or modeled.
Despite this abundance of structural information, the mechan-
istic details of catalysis, especially those that occur in the
membrane domain, remain poorly understood.
Heterozygous mutations in the human SDHB, SDHC or
SDHD genes cause paraganglioma or pheochromocytoma [7–
9]. Pheochromocytomas are catecholamine-secreting tumors
that arise in the adrenal medulla and are usually benign. They
can develop in extra-adrenal ganglia, in which case they are
often referred to as paraganglioma. The most common site of
paraganglioma is the carotid body, an organ involved in oxygen
sensing. Thus, it has been proposed that the SdhB, SdhC, and
SdhD subunits may be critical components of an oxygen-
sensing system [10]. Interestingly, paraganglioma appears to be
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mountains, high altitude dwellers who chronically experience
hypoxia [11].
SDH mutations are also associated with premature aging.
The mev-1(kn1) mutation (Gly71Glu) in the Caenorhabditis
elegans cyt-1 gene, which encodes an Sdh3p homolog, results
in animals that are hypersensitive to methyl viologen (paraquat,
a free radical generator) and to hyperoxia [12]. Mutant animals
exhibit signs of premature aging, defects in apoptosis and have a
shortened lifespan that can be extended with free radical
scavenging compounds [13,14]. The mev-1 mutation, which
affects an amino acid at the QP site, leads to an elevated
production of superoxide [15].
Three models have been proposed to explain how SDH
dysfunction can lead to tumor development [16]. First, defects
in SDH or elsewhere in the MRC may render cells more
resistant to apoptosis, contributing to tumor development. In a
second model, decreased or defective SDH activity might lead
to an increased production of reactive oxygen species and to an
aberrant regulation of apoptosis or response to hypoxia [17].
Finally, succinate, which accumulates as a result of SDH
dysfunction, might lead to the stabilization and activation of
hypoxia inducible factor (HIF) by directly inhibiting HIF prolyl
hydroxylase [18,19]. The prolyl hydroxylase is responsible for
oxygen-dependent posttranslational modifications of HIF that
promote its translocation to the nucleus.
To better understand the molecular bases of pathogenic SDH
mutations, we have investigated the role of the QP site residue
Sdh4p Tyr-89. Paraganglioma develops when the equivalent
tyrosine is mutated to cysteine in the human SDHD subunit. We
substituted several residues at position 89 and measured SDH
assembly, SDH activity, sensitivity to oxidative stress and
superoxide production. Our data indicate that Tyr-89 has an
essential role in ubiquinone reduction. We did not detect
increased superoxide production in any of the Tyr-89 mutant
enzymes, arguing against a causative role for reactive oxygen
species in tumor formation.
2. Materials and methods
2.1. Strains, media and culture conditions
The S. cerevisiae strain, YPH499 (MATα, ura3-52, lys2-801amber, ade2-
101ochre, his3Δ200, leu2Δ1, trp1Δ63, ρ+) was obtained from Stratagene (La
Jolla, CA). sdh4w5 (YPH499, sdh4::TRP1) contains a complete deletion and
replacement of the SDH4 gene by the selectable marker TRP1. The E. coli strain
DH5α was used for all genetic manipulations [20]. The yeast media (YPD,
YPG, SD, SG, YPGal, SGal, YPD+0.6%D and semisynthetic medium SS) and
culture conditions have been reported [20,21]. The respiratory capacities of
mutants were determined as the maximal optical densities attained in SS
medium with limiting galactose (0.1–0.3%) after ∼100 h of growth [20].
Oxygen or paraquat sensitivity were measured by growing aliquots of serially-
diluted cultures on plates incubated at 30 °C in an anaerobic jar continuously
flushed with ∼20 ml/min pure oxygen or in the presence of 0.5–1.0 mM
paraquat [22].
2.2. Construction of mutants
Site-directed mutagenesis was performed by PCR as described [23] using
two complementary mutagenic primers and forward and reverse flankingprimers containing BglII and XhoI restriction sites, upstream and downstream of
the SDH4 gene, respectively. pSDH4–17 is a 6.1-kb plasmid in the vector
pRS416 containing the entire SDH4 gene (546 coding nucleotides) as well as
156 bp upstream and 588 bp downstream. Mutations were confirmed by
sequencing the entire insert in both directions. Sequencing reactions were
performed by the Department of Biochemistry DNACore Facility (University of
Alberta, Edmonton, AB, Canada).
Saturation mutagenesis was performed with the forward oligonucleotide (5′-
CTCTTTCAGAAATNVNATCGGTGATACAAGAG-3′), which contains a
degenerate codon (underlined). The degenerate NVN (N=any nucleotide,
V=A, G or C) codon can introduce all possible amino acid substitutions at
position 89 in Sdh4p except tyrosine. A complementary oligonucleotide was
also prepared. PCR products were separated electrophoretically in agarose gels,
excised and purified with the QIAEX® II gel extraction kit (Qiagen Inc.),
digested with BglII and XhoI and ligated into pRS416 cut with BamHI and XhoI
to create a library of SDH4 codon 89 mutants. The library was transformed into
sdh4w5 and plated on SG plates containing 0.1% glucose. The 20 largest
colonies from over 1600 transformants were selected. The plasmids were
recovered and sequenced (coding, promoter and downstream sequences).
2.3. Computational methods
All molecular dynamics simulations were carried out using the GROMACS
3.3 package [24] with the GROMOS96 force field. Simulations were performed
under the conditions of constant pressure, constant temperature, and constant
particle number (NpT ensemble). Temperature was set at 325 K using the
Berendsen thermostat, while anisotropic pressure was maintained at 1 atm using
the Parrinello–Rahman barostat. The yeast SDH (coordinates 1PB4 [6]) was
inserted into dipalmitoylphosphatidylcholine (DPPC) bilayer, solvated with
simple point charge (SPC) water. Sdh1p was removed to reduce the intensity of
the computation as it does not contribute to quinone binding. The starting
membrane model was a pre-equilibrated 64 DPPC [25], which was modified to
271 DPPC and 23,553 SPC water in order to accommodate the protein. The
protein was position-restrained for 500 ps to allow the lipid to equilibrate. This
was followed by a 500 ps equilibration of the whole system without restraints.
For free energy calculations, the system was further equilibrated for 500 ps,
followed by 1 ns production runs. A conformational search simulation was
performed to determine if ubiquinone binding differed in the mutant QP sites.
The mutant SDHs were equilibrated into a solvated bilayer and an extended
simulation of 2 ns was performed. The mutant SDH structures were then
superimposed on the wild type and the ubiquinone binding sites compared. All
molecular dynamics computations were carried out on the University of Alberta
3.8 GHz Intel Pentium 4 processor 44-node Linux cluster.
The mutational free energy changes in the native and denatured states (Fig.
1) are calculated by the thermodynamic integration (TI) equation:
DG ¼
Z 1
0
BHðkÞ
Bk
 
k
dk ð26Þ
whereH(λ) is an intermediate Hamiltonian and λ is a coupling constant between
the wild-type (λ=0) and mutant (λ=1). The bracket < >λ denotes ensemble
average for the system characterized by the Hamiltonian H(λ). H(λ) is scaled
from λ=0 to λ=1 by increments δλ=0.04 (slow-growth, 25 intermediate λ
states). Short peptide models were used to model the denatured state and reduce
the intensity of the computations [26].
2.4. Isolation of mitochondria and enzyme assays
Cultures grown in YP+0.6%D to late stationary phase (72–96 h were
harvested by centrifugation, washed with ddH2O, and resuspended in a HEPES
buffer (20 mMHEPES–KOH, pH 7.4, 1 mM EDTA) at 0.6 g/ml yeast cells (wet
weight). Complete protease inhibitor cocktail tablets (Roche Diagnostics) and
1 mM phenylmethylsulfonyl fluoride (PMSF) were added just prior to cell lysis
by three passes (at 16,000–18,000 psi) through a French pressure cell (American
Instrument Company, Silver Spring, Maryland) [27]. Enzyme assays were
performed as described [20]. Superoxide production was assayed as the
malonate-sensitive, superoxide dismutase-sensitive reduction of cytochrome c
using superoxide dismutase from bovine erythrocytes (catalog number S-2515,
Table 1
Plasmids recovered from the saturation mutagenesis
Codon-89
sequence
Amino acid
substitution
Additional mutations a
1 AGG Arg
2 CTG Leu C→T at +266 (T89I).
Not further analyzed.
3 ACG Thr Single base deletion at +531.
Not further analyzed.
4 GGG Gly G→A at +231 (L77I).
Not further analyzed.
5 CCC Pro C→T at −23 and T→C at −50.
Not further analyzed.
6 TCG Ser
7 TCC Ser A→G at +490 (S133G).
Not further analyzed.
8 AGG Arg Multiple mutations.
Not further analyzed.
9 AGA Arg
10 ATA Ile Silent T→C transition
at +258 (A86A).
11 AGA Arg
12 ACT Thr
13 TCG Ser
14 AGG Arg
15 ACG Thr
16 CGG Arg
a The nucleotides are numbered from the first position of the start codon.
Fig. 1. The thermodynamic cycle used in the free energy calculation. A capped
25-amino acid residue peptide in an extended structure was used to model the
denatured state [26,36]. To validate the approach, the denatured state of the wild
type protein containing a Y89A mutation was simulated in vacuo at 1000 K for
2 ns and then solvated in DPPC. The result of the relative free energy calculated
with this approach was compared with 5 to 25-residue peptide models; the 25-
residue peptide was found to be in close agreement with the simulated denatured
state of the protein [26]. In addition, our results show that the 25-mer unfolded
state model is the most stable calculation and demonstrates the lowest hysteresis.
For the mutants, capped 25-residue peptides with the mutation in the middle,
were used to model the denatured states. The free energy difference between the
wild-type and mutant proteins (ΔΔG) is defined as the difference between the
mutational free energy changes in the native state and in the denatured state [26]:
ΔΔGf =ΔG1−ΔG2=ΔG3−ΔG4. (SDHf)WT and (SDHu)WT are the folded and
the unfolded wild type proteins, respectively, while (SDHf)MUT and (SDH
u)MUT
correspond to the folded and the unfolded mutant proteins, respectively. The
alchemical paths ΔG3 and ΔG4 were calculated by molecular dynamics.
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confirmed to be succinate-dependent.
2.5. Miscellaneous methods
Measurements of covalently attached flavin and protein contents, yeast and
E. coli transformation, and recombinant DNA methods have been described
[28].
3. Results
Sdh4p Tyr-89 was substituted with phenylalanine and
cysteine. A phenylalanine removes the hydrogen bonding
properties of the tyrosine side chain while preserving the
aromatic ring; this should result in a minimal structural
perturbation. Tyr-89 was also substituted with cysteine because
in humans, SdhD Y114C is linked to head and neck
paraganglioma [29].
To discover whether any other residues could effectively
substitute for Tyr-89, we constructed degenerate oligonucleo-
tides that could lead to the insertion of all possible amino acids
at codon 89. The oligonucleotides were used in PCR
mutagenesis to create a pool of codon-89 mutants. We
transformed this pool into the SDH4 null strain sdh4w5 and
obtained more than 1600 transformants. These were tested for
growth on SG plates containing 0.1% glucose. Respiration
deficient transformants form small colonies by fermenting
glucose; respiration competent transformants continue growing
to form larger colonies. We recovered and sequenced the
plasmids from the 20 largest colonies; four of these encoded a
tyrosine at position 89 and were not further analyzed (Table 1).The Y89I mutant was unexpected because the isoleucine side
chain is apolar. To confirm the partial complementation for
respiratory growth, we isolated the plasmid and re-transformed
it into fresh sdh4w5. These new transformants could also form
larger colonies on SG plates containing 0.1% glucose. The
plasmid was re-sequenced and the nucleotide changes con-
firmed (number 10, Table 1).
We measured the growth yields of the Tyr-89 mutants on
semisynthetic medium containing 0.1–0.3% galactose. An
initial fermentative growth is followed by a respiratory phase
when fermentable carbon source is limiting. Respiratory
function contributes to the final growth yield even if the
amount of respiratory function is insufficient to support growth
in the absence of fermentation, as it is in the Tyr-89 mutants.
The optical densities at 600 nm of late stationary phase cultures
were measured (Fig. 2). The SDH4 deficient strain containing
an empty vector has a growth yield of 16% compared to when it
contains the wild type SDH4 gene. The growth yields of the
Y89C and Y89F mutants do not differ from that of the SDH4
deletion strain. The Y89I, Y89T, Y89S, and Y89R mutants have
growth yields ranging from 24 to 39% of wild type,
significantly more than the SDH4 deletion strain, indicating
the mutant enzymes support some respiratory growth. The
respiratory capabilities of all mutants correlate well with their
colony sizes on SG plates containing 0.1% glucose.
To measure the effects of the mutations on enzyme assembly,
we measured the levels of covalent FAD in mitochondrial
membranes (Table 2). SDH is the major covalent flavoprotein in
S. cerevisiae and the covalent flavin levels in mitochondrial
membrane fractions reflect the extent of SDH assembly [30].
The covalent FAD contents of the mutant membranes are
Table 3
Stability of the Tyr-89 mutants calculated from molecular dynamics simulations
Mutant ΔΔG a (kcal mol−1)
Y89F −0.27
Y89C −0.63
Y89S −1.15
Y89I −1.40
Y89T −1.44
Y89R −1.51
a The unfolding free energies are calculated using the equation: Δ(ΔG)=
ΔGMUT−ΔGWT.
Fig. 2. Growth of strains on galactose medium. Strains were grown at 30 °C on
semisynthetic liquid medium containing 0.1–0.3% galactose and the optical
densities at 600 nm were measured. The relative growth yields were calculated
using the final optical density values on 0.3% galactose. Each point represents
the average of 4 or more independent cultures.
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from 60% (Y89T) to 85% (Y89S), indicating that enzyme
assembly is largely unaffected by the Tyr-89 mutations.
The malonate-sensitive, succinate-PMS/DCPIP reductase
assay measures the activity of the SDH catalytic domain
attached to the membrane; the enzyme does not require a
catalytically competent membrane domain for this activity. The
specific activities of all mutants are lower than the wild type,
ranging from 41% (Y89F) to 69% (Y89I) (Table 2), indicating
SDH assembly is not greatly impaired (∼2-fold or less). There
is residual covalent flavin and malonate-sensitive, succinate-
PMS/DCPIP reductase activity in the deletion mutant, which we
suspect are attributable to the expression of one or both of the
Sdh4p paralogs found in the S. cerevisiae genome; the amount
of residual SDH is strain-dependent [1].
To further explore the effects of the Tyr-89 mutations on
SDH stability, we compared the calculated unfolding free
energies of the mutants to the wild type using the equation:
ΔΔG=ΔGMUT−ΔGWT. A negative free energy difference
(ΔΔG) indicates that the mutation destabilizes the protein. The
Tyr-89 mutations have minor effects on enzyme stability, withTable 2
Assembly of the mutant enzymes
Strain Covalent FADa Specific activity b Turnover number c
Y89-wild type 16±1 (100%) 80±10 (100%) 4800±600 (100%)
Y89S 13.7±0.3 (85%) ⁎ 50±5 (64%) ⁎ 3600±300 (75%) ⁎
Y89T 9.7±0.4 (60%) ⁎ 36±3 (47%) ⁎ 3800±200 (78%) ⁎
Y89I 10.7±0.7 (67%) ⁎ 54±7 (69%) ⁎ 5000±400 (104%)
Y89R 10.6±0.5 (66%) ⁎ 39±4 (51%) ⁎ 3700±200 (77%) ⁎
Y89C 14±1 (84%) ⁎ 42±4 (54%) ⁎ 3100±300 (63%) ⁎
Y89F 11.2±0.8 (70%) ⁎ 32±3 (41%) ⁎ 2800±200 (58%) ⁎
ΔSDH4 4.2±0.3 (26%) ⁎ 8.1±0.7 (10%) ⁎ 1000±100 (20%) ⁎
a Covalent flavin contents are expressed as pmol FAD mg of protein−1. Each
value represents the mean of quadruplicate determinations±S.E.
b Specific activities are expressed as μmol of PMS-mediated DCPIP reduced
min−1 mg of protein−1.
c Turnover numbers are expressed as μmol of PMS-mediated DCPIP reduced
min−1 μmol of covalent FAD−1.
⁎ P<0.01 using a two-tailed unpaired Student's t-test compared to the
wild-type.free energy changes of less than 1.5 kcal mol− 1 (Table 3). A
buried intramolecular hydrogen bond is estimated to increase
protein stability by ∼1.5±1.0 kcal mol− 1 [31]. The magnitudes
of the unfolding free energy changes associated with the Tyr-89
mutations suggest that any changes to the enzyme structure are
minor. The flavin contents, the succinate-PMS/DCPIP activities
and the energy calculations all suggest that the Tyr-89 mutations
do not induce large structural perturbations. None of the
mutations reduces the turnover numbers for the mutant enzymes
in the succinate-PMS/DCPIP reductase assay by more than 1.7-
fold.
To explore the effects of the mutations on electron transfer,
we assayed the succinate-dependent reduction of either
exogenous quinone (succinate-DB reductase activity) or of
exogenous cytochrome c (succinate-cytochrome c reductase
activity). The latter assay depends on complexes II and III of the
respiratory chain and on endogenous ubiquinone. In sharp
contrast to the succinate-PMS/DCPIP reductase activities,
which are reduced by 2-fold or less, the quinone reductase
activities were drastically reduced (Table 4). The succinate-
cytochrome c reductase activities of the Tyr-89 mutants are all
reduced by 20-fold or greater and are just slightly higher than
that observed in the SDH4-deficient control.
To determine whether the Tyr-89 mutations reduce the
affinity of the QP sites for quinone, we measured the succinate-
DB reductase activities in the presence of higher concentrations
of DB. As expected, the activity of the wild type enzyme is notTable 4
Quinone-reductase activities of the mutant enzymes
Strain Succinate-DB
reductase activity a
Succinate-cytochrome c
reductase activity b
Y89-wild type 3600±700 (100%) 2400±300 (100%)
Y89S 470±80 (13%) ⁎ 77±7 (3%) ⁎
Y89T 440±90 (12%) ⁎ 66±4 (3%) ⁎
Y89I 500±100 (14%) ⁎ 120±30 (5%) ⁎
Y89R 470±90 (13%) ⁎ 100±10 (4%) ⁎
Y89C 380±40 (11%) ⁎ 37±5 (2%) ⁎
Y89F 190±40 (5%) ⁎ 26±3 (1%) ⁎
ΔSDH4 170±40 (5%) ⁎ 38±7 (2%) ⁎
a Activities are expressed as μmol of DB-mediated DCPIP reduced min−1
μmol of covalent FAD−1.
b Activities are expressed as μmol of cytochrome c reduced min−1 μmol of
covalent FAD−1.
⁎ P<0.01 using a two-tailed unpaired Student's t-test compared to the
wild-type.
Fig. 3. Dependence of SDH turnover number on decylubiquinone concentration.
The succinate-DB reductase assay is normally performed with 50 μM DB (final
concentration). Activity values are expressed as turnover numbers (μmol DB
reduced min−1 μmol of covalent FAD−1). Each point represents the average of 4
or more independent measurements.
Fig. 4. Effect of Sdh4p Tyr-89 (Tyr D89) mutations on the ubiquinone binding pocke
solvated DPPC. Panels A to E depict the environments of bound quinone in the wild ty
the end of the simulation. Panel F depicts the superposed ubiquinone positions from
type; red, Y89F; green, Y89I; blue, Y89R; yellow, Y89S.
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500 μM (Fig. 3). In addition, pre-incubation of the mutant
enzymes with 250 μM DB also does not increase DB reductase
activity (not shown). These data indicate that the reduced
quinone reductase activities of the mutants are not due to a
decreased affinity of the QP sites for quinone substrates. The
low residual activities of the Tyr-89 mutants prevented us from
determining their apparent affinities for DB.
We explored the structure of quinone-binding site in the wild
type and the mutants computationally. The starting coordinates
were the S. cerevisiae SDH model 1PB4 [6]. We predicted that
the Tyr-89 mutations might cause ubiquinone to bind in a
different position within the QP site or to adopt a different
orientation within while bound at the same location. Our
computational results argue against large changes in the
architecture of the QP site. Additionally, there were no
significant differences in the position or orientation of boundt. The structures of the wild type and mutant proteins were simulated for 2 ns in
pe enzyme (A), and the Y89I (B), Y89S (C), Y89R (D), and Y89F (E) mutants at
the averaged, minimized structures of the last 500 ps of simulation. White, wild
Table 5
Superoxide generation by the mutant enzymes
Strain Total activity a Complexes II+ III-
dependent activity b
Superoxide-
mediated activity c
Y89-wild type 2257±300 (100%) 2204 (98%) 53 (2%)
Y89S 69±7 (3%) ⁎ 62 (90%) 7 (10%)
Y89T 63±4 (3%) ⁎ 58 (92%) 5 (8%)
Y89I 112±30 (5%) ⁎ 104 (93%) 8 (7%)
Y89R 94±10 (4%) ⁎ 83 (89%) 10 (11%)
Y89C 30±5 (2%) ⁎ 23 (76%) 7 (24%)
Y89F 24±3 (1%) ⁎ 18 (72%) 7 (28%)
ΔSDH4 40±7 (2%) ⁎ 31 (78%) 9 (22%)
a Activities are expressed as the total μmol of cytochrome c reduced min−1
μmol of covalent FAD−1. Percentages compare activities to the wild type level.
b Activities are expressed as μmol of cytochrome c reduced min−1 μmol of
covalent FAD−1 by complex III. Percentages refer to the portion of the total
activity.
c Activities are expressed as the μmol of cytochrome c reduced min−1 μmol of
covalent FAD−1 by a superoxide dismutase-sensitive pathway. Percentages refer
to the portion of the total activity.
⁎ P<0.01 using a two-tailed unpaired Student's t-test compared to the
wild-type.
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simulation (2 ns), the equilibrium position coincided with the
original position of the Q [2] (Fig. 4). That the quinone remains
bound suggests that intermolecular forces other than hydrogen-
bonding (electrostatic and van der Waals forces such as ring
stacking) contribute significantly to quinone binding. A more
detailed analysis of the forces contributing to quinone binding
will be presented elsewhere.
Superoxide production was assayed as the malonate-
sensitive, superoxide dismutase-sensitive cytochrome c reduc-
tase activity in the presence of cyanide to inhibit cytochrome c
oxidase [22]. Two pathways of electron transfer can be used
reduce cytochrome c: in the first, electrons flow through SDH to
ubiquinone, through complex III and to cytochrome c; in the
second pathway, a superoxide anion directly reduces cyto-
chrome c. Superoxide dismutase will inhibit the second
pathway by converting superoxide into hydrogen peroxide,
but will have no effect on the first pathway. In each of the Tyr-
89 mutants, we measured significantly decreased rates of
superoxide production compared to the wild type (Table 5). It
should be noted, however, that the superoxide-mediated
pathway accounted for a larger fraction of the total enzyme
activity in the mutants than in the wild type.
4. Discussion
Our results indicate that Sdh4p Tyr-89 is essential for
efficient quinone reductase activity. In our saturation mutagen-
esis of codon 89, only a tyrosine was found to support full
respiratory growth; all other substitutions completely abolished
growth on SG medium. However, when a small amount of
glucose was added to the SG medium, we observed a variety of
colony sizes, indicating that some of the colonies had limited
respiratory capacity. When these Tyr-89 substitutions were
recovered and the plasmids sequenced, we found that Ile, Ser,
Thr, or Arg substitutions were able to support limited SDHactivity that was 2–3 fold higher than in the knockout strain
(Table 4). These observations suggest that the tyrosine side
chain has some chemical or structural property that is uniquely
suited to its role in catalysis. This is consistent with the
observation that in all succinate:ubiquinone oxidoreductase
sequences examined to date, a tyrosine is absolutely conserved.
The dramatic losses of quinone reductase activity observed
in the Tyr-89 mutants are not due to disruption of SDH
assembly or stability. For example, when Tyr-89 is replaced
with Phe or Cys, the enzymes are almost completely inactive as
quinone reductases (Table 4), yet assembled with reasonable
efficiency as measured by covalent flavin contents and by
membrane associated succinate-PMS/DCPIP reductase activ-
ities (Table 2). Our computational studies also support this
conclusion; the 6 amino acid substitutions we examined do not
result in large changes in unfolding free energies (Table 3).
Therefore, we conclude that the loss of Tyr-89 has only minor
structural consequences but severe catalytic ones.
The precise mechanisms of SDH-mediated ubiquinone
reduction remain poorly understood. When the E. coli SDH
was crystallized and its structure solved, density corresponding
to one molecule of ubiquinone was found at the QP site [2]. It is
at this site that the inhibitors TTFA (thenoyl trifluoroacetone)
and carboxin bind to the avian and pig enzymes [4,5]. The E.
coli structure revealed that SdhD Tyr-83 and SdhB Trp-164 are
direct ligands of the O1 atom of ubiquinone [2]. It was noted
that Tyr-83 also formed a hydrogen bond with SdhC Arg-31,
which could reduce the pKa of the tyrosine side chain, allowing
it to serve as direct proton donor during quinone reduction [2].
In the E. coli structure, no amino acid side chain was located in
the vicinity of the ubiquinone O4 carbonyl oxygen, leading to
the suggestion that a water molecule might serve as proton
donor. In our model of the S. cerevisiae SDH, Sdh4p Tyr-89 and
Sdh3p Ser-44 are within hydrogen bonding distance of the O1
and O4 atoms of the docked ubiquinone, respectively [6].
More recently, a mechanism for the reduction of ubiquinone
by the E. coli SDH has been proposed based on additional
structural and computational studies [3]. In this mechanism, the
ubiquinone is believed to rotate from an initial binding site
called Q1, which corresponds to the position of the ubiquinone
seen in the original crystal structure [2], to a computationally-
determined second site called Q2 in which the O4 carbonyl
group now hydrogen bonds with SdhC Ser-27 and the O3
methoxy group hydrogen bonds with SdhB His-207. The Q2
site more closely resembles the position of the docked
ubiquinone in our yeast model [6]. The hydrogen bond between
SdhD Tyr-83 and the O1 carbonyl group of ubiquinone serves to
anchor the quinone during the rotation. Following movement
into the Q2 position, the ubiquinone is reduced by the almost
simultaneous delivery of an electron from each of the [3Fe–4S]
cluster and the heme. Protonation via water-39 disrupts the
hydrogen bonds with Tyr-83, Ser-27 and His-207 and allows
ubiquinol to depart.
Our data are consistent with a more significant role for
Sdh4p Tyr-89 than what is proposed for E. coli SdhC Tyr-83
[3]. Tyr-89 has an essential role in quinone reduction in the
yeast SDH. The catalytic activities of the mutant enzymes are
149Y. Silkin et al. / Biochimica et Biophysica Acta 1767 (2007) 143–150not stimulated by 5-fold higher DB levels, suggesting that the
drops in activity in the Tyr-89 mutants cannot simply be
ascribed to a decreased affinity for quinone. In other quinone-
binding site mutations we have investigated, activities could be
increased with higher substrate concentrations [32]. Further-
more, our computational studies do not indicate that the Tyr-89
mutations significantly interfere with ubiquinone binding; the
quinone remains at the initial binding site in the 1PB4
coordinates; this site corresponds to the Q2 position of the E.
coli SDH [2]. The simplest explanation is that Tyr-89, in
addition to hydrogen bonding to the quinone, is a proton donor
during quinone reduction. We suggest that, as originally
proposed for the E. coli SdhC Tyr-83 [2], Tyr-89 donates a
proton to the O1 carbonyl of the quinone during the formation
of ubiquinol and that protonation is essential for efficient
catalysis. The residual activities of the Tyr-89 mutants in
quinone reduction are likely due to the presence of inefficient
alternate proton donors or water.
Mutations in the human SDHD gene are associated with the
development of paragangliomas and pheochromocytomas. It
has been suggested that these tumors develop because of an
SDH-mediated increased generation of reactive oxygen species
[17]. Specific mutations that affect the quinone-binding sites in
the C. elegans complex II [12,15], in the E. coli fumarate
reductase [33] or in the yeast SDH [22] do produce oxidative
stress. We modeled the human SDHD Y114C mutation, which
is associated with paraganglioma and carotid body tumors
[34]. The yeast Sdh4p Y89C mutation does not greatly impair
SDH assembly but it results in a complete loss of quinone
reductase activity. Mitochondria from the Y89C mutant
produce 7–8 fold less superoxide than wild type mitochondria
(Table 5). The Y89C mutant is not hypersensitive to paraquat,
also suggesting it is not under superoxide stress (results not
shown). The mutant is however somewhat sensitive to
hyperoxia on SGal medium, suggesting there may be some
generation of reactive oxygen species other than superoxide
under specific growth conditions. A likely source of these
reactive oxygen species would be the flavin located at the
active site [35]. Our results do not support a model that
involves the SDH-mediated generation of superoxide free
radicals as the cause of paraganglioma. Rather, the Y89C
mutant with its complete loss of activity, likely leads to
elevated levels of succinate and the induction of hypoxia-
inducing factor [18,19]. This latter model also provides a
plausible explanation for paraganglioma alleles that truncate or
eliminate one of the SDH subunits and likely prevent enzyme
assembly [9].
In summary, our results indicate that Tyr-89 performs an
essential step in ubiquinone reduction. We propose that Tyr-89
is a proton donor to the O1 carbonyl of the quinone. Our data
also argue against a role for elevated production of reactive
oxygen species in tumor formation.
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